The RAGE axis in early diabetic retinopathy

Area of Science:

• Ophthalmology
• Endocrinology
• Molecular Biology

Background:

• The receptor for advanced glycation end products (AGEs) is implicated in diabetic complications.
• The RAGE axis plays a role in the pathogenesis of diabetic retinopathy.

Purpose of the Study:

• To characterize the role of the RAGE axis in nonproliferative diabetic retinopathy (NPDR) using a murine model.
• To investigate the therapeutic potential of RAGE blockade in early diabetic retinopathy.

Main Methods:

• Utilized hyperglycemic, hyperlipidemic (HGHL) mice (apolipoprotein E(-/-) db/db) to model NPDR.
• Assessed retinal vascular lesions, neural function (electroretinography), and quantified the AGE/RAGE axis via immunohistochemistry, RT-PCR, autofluorescence, and ELISA.
• Administered soluble RAGE to evaluate the impact of RAGE blockade.

Main Results:

• HGHL mice showed early inner retinal neuronal dysfunction and accelerated development of retinal vascular lesions (acellular capillaries, pericyte ghosts).
• AGEs accumulated in the vitreous cavity and internal limiting membrane, associated with RAGE-expressing Müller cells.
• Soluble RAGE treatment ameliorated neuronal dysfunction and reduced capillary lesions, indicating RAGE axis involvement.

Conclusions:

• The RAGE axis is amplified in the retina during early NPDR, particularly at the vitreoretinal interface.
• Antagonism of the RAGE axis effectively reduces neurovascular perturbations in NPDR.
• The RAGE axis represents a promising therapeutic target for early diabetic retinopathy intervention.